It is primarily recognized for its therapeutic effects for treating sexual dysfunction, specifically hypoactive sexual desire disorder (HSDD) in both men and women (1)
The Phase 3 ATTAIN-1 trial had good results that led to this approval, but not all positive: 12.4% average weight loss (27.3 lbs) at highest dose Lower than the 15-20% weight loss seen with injectables Wegovy and Zepbound Nearly 1/4 of participants on the highest dose reported vomiting Vomiting rates are much higher than injectable GLP-1s However, there is likely a niche for Foundayo (along with the pill version of Wegovy) due to convenience: No refrigeration requirements or injection site reactions Eliminates barriers for patients avoiding injectables due to stigma, needle aversion, or storage constraints It's possible we could see this as a "maintenance" therapy after an initial injectable course
For some, GLP-1s provide a path forward when everything else has failed
Chronic sleep issues worsen other menopause symptoms, particularly mood problems, memory difficulties, and daytime exhaustion [3]
This is typically temporary and improves as intake stabilizes and weight settles
In addition, most patients elect to receive medication that relaxes them during the procedure
